Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of analysts have commented on the stock. B. Riley reiterated a “neutral” rating and issued a $1.00 price target (down previously from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Rodman & Renshaw reiterated a “buy” rating and set a $14.00 price target on shares of Cognition Therapeutics in a report on Tuesday, July 2nd. Cantor Fitzgerald lowered Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 30th. HC Wainwright reduced their target price on Cognition Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Chardan Capital assumed coverage on Cognition Therapeutics in a report on Thursday, June 6th. They set a “buy” rating and a $11.00 target price on the stock.

Hedge Funds Weigh In On Cognition Therapeutics

A number of large investors have recently made changes to their positions in the company. Twin Focus Capital Partners LLC acquired a new position in Cognition Therapeutics in the 4th quarter valued at $173,000. Hohimer Wealth Management LLC bought a new position in Cognition Therapeutics during the first quarter worth about $410,000. Tocqueville Asset Management L.P. acquired a new stake in Cognition Therapeutics in the 1st quarter worth about $47,000. CM Management LLC bought a new stake in Cognition Therapeutics in the 1st quarter valued at about $318,000. Finally, AWM Investment Company Inc. bought a new position in shares of Cognition Therapeutics during the first quarter worth approximately $1,183,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Stock Performance

CGTX opened at $0.58 on Friday. The business’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.61. The firm has a market capitalization of $23.22 million, a PE ratio of -0.63 and a beta of 1.41. Cognition Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.95.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. During the same period last year, the company posted ($0.16) earnings per share. On average, research analysts forecast that Cognition Therapeutics will post -0.87 earnings per share for the current year.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.